X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA LUPIN LTD AJANTA PHARMA/
LUPIN LTD
 
P/E (TTM) x 19.5 164.2 11.9% View Chart
P/BV x 4.5 3.1 146.8% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 AJANTA PHARMA   LUPIN LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
LUPIN LTD
Mar-17
AJANTA PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,8181,750 103.9%   
Low Rs1,1061,384 79.9%   
Sales per share (Unadj.) Rs239.5387.4 61.8%  
Earnings per share (Unadj.) Rs52.856.6 93.2%  
Cash flow per share (Unadj.) Rs59.576.8 77.4%  
Dividends per share (Unadj.) Rs07.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs230.0298.9 76.9%  
Shares outstanding (eoy) m88.77451.58 19.7%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x6.14.0 151.0%   
Avg P/E ratio x27.727.7 100.1%  
P/CF ratio (eoy) x24.620.4 120.5%  
Price / Book Value ratio x6.45.2 121.3%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m129,782707,513 18.3%   
No. of employees `0006.816.8 40.5%   
Total wages/salary Rs m3,76528,495 13.2%   
Avg. sales/employee Rs Th3,128.410,418.3 30.0%   
Avg. wages/employee Rs Th554.01,697.0 32.6%   
Avg. net profit/employee Rs Th689.71,523.0 45.3%   
INCOME DATA
Net Sales Rs m21,258174,943 12.2%  
Other income Rs m2421,065 22.7%   
Total revenues Rs m21,499176,008 12.2%   
Gross profit Rs m6,58444,931 14.7%  
Depreciation Rs m5969,122 6.5%   
Interest Rs m41,525 0.3%   
Profit before tax Rs m6,22635,349 17.6%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5399,785 15.7%   
Profit after tax Rs m4,68625,575 18.3%  
Gross profit margin %31.025.7 120.6%  
Effective tax rate %24.727.7 89.3%   
Net profit margin %22.014.6 150.8%  
BALANCE SHEET DATA
Current assets Rs m12,236119,542 10.2%   
Current liabilities Rs m3,46161,206 5.7%   
Net working cap to sales %41.333.3 123.8%  
Current ratio x3.52.0 181.0%  
Inventory Days Days6076 79.2%  
Debtors Days Days8490 94.0%  
Net fixed assets Rs m11,140131,660 8.5%   
Share capital Rs m177903 19.6%   
"Free" reserves Rs m20,237134,073 15.1%   
Net worth Rs m20,414134,976 15.1%   
Long term debt Rs m1056,478 0.0%   
Total assets Rs m24,486266,073 9.2%  
Interest coverage x1,519.424.2 6,285.1%   
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x0.90.7 132.0%   
Return on assets %19.210.2 188.1%  
Return on equity %23.018.9 121.2%  
Return on capital %30.519.3 158.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66781,885 14.2%   
Fx outflow Rs m1,61621,506 7.5%   
Net fx Rs m10,05260,378 16.6%   
CASH FLOW
From Operations Rs m2,85441,148 6.9%  
From Investments Rs m-2,604-25,287 10.3%  
From Financial Activity Rs m-24,332 -0.0%  
Net Cashflow Rs m24820,193 1.2%  

Share Holding

Indian Promoters % 73.8 46.6 158.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 1.6 11.3 13.7%  
FIIs % 7.6 31.9 23.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.1 168.3%  
Shareholders   20,968 98,259 21.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT LTD.  GSK PHARMA  PLETHICO PHARMA  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jun 25, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS